Synageva BioPharma (GEVA)
Synageva BioPharma Liabilities: 17.42M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
GEVA Liabilities Rankings
| Overall | 88th percentile | 500 of 4384 |
| Sector | 68th percentile | 159 of 504 in Healthcare |
| Industry | 57th percentile | 68 of 160 in Biotechnology |
GEVA Liabilities Range, Past 5 Years
| Minimum | 1.28M | Sep 2011 |
| Maximum | 27.82M | Jun 2007 |
| Average | 17.54M |
About Total Liabilities
Liabilities are obligations of a company arising from past transactions or events which are expected to reduce assets when they are settled.
Total liabilities is a line item on the balance sheet.
Learn More
You may also be interested in these GEVA related companies
GEVA News
$GEVA Insider Sale: $1.5M of stock sold by Carsten Boess on May 16, 2012 http://stks.co/3tvv
about 11 days ago by MarketBrief
about 11 days ago by MarketBrief
Synageva BioPharma to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 10, 7:00AM Business Wire
May 10, 7:00AM Business Wire
Synageva BioPharma to Host 2011 Fourth Quarter and Full Year Financial Results Conference Call on March 15
Mar 08, 4:05PM Business Wire
Mar 08, 4:05PM Business Wire
JPMorgan Starts Synageva BioPharma (GEVA) at Overweight, Sets $50 Price Target
Feb 29, 7:57AM Street Insider
Feb 29, 7:57AM Street Insider
Synageva BioPharma to Present at the Cowen and Company 32nd Annual Healthcare Conference
Feb 28, 4:05PM Business Wire
Feb 28, 4:05PM Business Wire
RT @ChartSwingTrade $SZYM is a very interesting chart here/my second favorite after $GEVA
about 103 days ago by ivan_bg
about 103 days ago by ivan_bg
Its all about the volume. Someone wanted into this thin one today. Watching for new highs here $GEVA http://chart.ly/77u7yi6
about 104 days ago by lasertrader
about 104 days ago by lasertrader
Synageva BioPharma to Present at the Leerink Swann 2012 Global Healthcare Conference
Feb 14, 7:00AM Business Wire
Feb 14, 7:00AM Business Wire
$GEVA my 36 bid alert hit today on this RARE BIRD PATTERN. The elusive HIGH TIGHT FLAG: http://stks.co/2NlD
about 106 days ago by TCMLLC
about 106 days ago by TCMLLC
$GEVA is $36.100. I It is currently 0% above the actual breakout pivot. $GEVA is buy
about 106 days ago by sundeeptrade
about 106 days ago by sundeeptrade
Synageva BioPharma Announces Interim Data at 8th Annual Lysosomal Disease Network (LDN) World Symposium
Feb 09, 4:10PM Business Wire
Feb 09, 4:10PM Business Wire
Synageva BioPharma Highlights Key Data Presentations at Upcoming Lysosomal Disease Network (LDN) World Symposium
Jan 30, 7:00AM Business Wire
Jan 30, 7:00AM Business Wire
$GEVA Insider Buy: $30.2M of stock bought by Thomas Tisch on January 10, 2012 http://stks.co/1uXk
about 137 days ago by MarketBrief
about 137 days ago by MarketBrief
$GEVA Insider Buy: $30.2M of stock bought by Thomas Tisch on January 10, 2012 http://stks.co/1tEX
about 138 days ago by MarketBrief
about 138 days ago by MarketBrief
Synageva (GEVA) Underwriters Exercise Overallotment; Net Proceeds of $84M Expected
Jan 10, 8:58AM Street Insider
Jan 10, 8:58AM Street Insider
Synageva BioPharma Announces Closing of Public Offering and Exercise of Over-Allotment Option
Jan 10, 8:55AM Business Wire
Jan 10, 8:55AM Business Wire
$GEVA Announces Pricing of Public Offering of Common Stock at $25.18/Share
about 145 days ago by Benzinga
about 145 days ago by Benzinga
Synageva BioPharma Announces Pricing of Public Offering of Common Stock at $25.18 per Share
Jan 05, 8:35AM Benzinga
Jan 05, 8:35AM Benzinga
Synageva BioPharma Announces Pricing of Public Offering of Common Stock
Jan 05, 8:35AM Business Wire
Jan 05, 8:35AM Business Wire
Synageva BioPharma Announces $60 Million Proposed Public Offering of Common Stock
Jan 04, 4:03PM Benzinga
Jan 04, 4:03PM Benzinga
Wedbush Starts Synageva BioPharma (GEVA) at Outperform; Focused on Rare Diseases With Its Golden Eggs
Dec 13, 7:04AM Street Insider
Dec 13, 7:04AM Street Insider
Synageva BioPharma to Present at the 30th Annual J.P. Morgan Healthcare Conference on January 11, 2012
Dec 12, 8:00AM Business Wire
Dec 12, 8:00AM Business Wire
Synageva BioPharma to Present at Lazard Capital Markets 8th Annual Healthcare Conference on November 15, 2011
Nov 09, 8:00AM Business Wire
Nov 09, 8:00AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GEVA | 37.84 | -0.35 | -0.92% | 801.07M |
| GET | 34.22 | -0.28 | -0.81% | 1.661B |
| GES | 27.11 | +0.41 | +1.54% | 2.432B |
| GERN | 1.42 | +0.03 | +2.16% | 187.81M |
| GEOY | 20.39 | +1.29 | +6.75% | 453.47M |
| FVE | 3.05 | -0.03 | -0.97% | 146.10M |
| FVD | 16.26 | -0.02 | -0.12% | |
| FURX | 19.10 | +0.88 | +4.83% | 190.04M |
| FUR | 10.30 | -0.10 | -0.96% | 340.42M |
| FUND | 6.26 | +0.06 | +0.97% |